Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3417-3419

  Durán Valle, María Teresa ^a   Gago, Sara ^b   Gómez López, Alicia ^b   Cuenca Estrella, Manuel ^b   Díez Canseco, Leticia Jiménez ^a   Gómez Garcés, José Luis ^a   Zaragoza, Oscar ^b  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE;

ABDOMINAL RADIOGRAPHY; ABDOMINAL SURGERY; AGED; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BILIARY TRACT SURGERY; CANDIDA GLABRATA; CANDIDEMIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; FKS2 GENE; FUNGAL COLONIZATION; FUNGAL GENE; FUNGUS CULTURE; FUNGUS ISOLATION; GENE MUTATION; HUMAN; INTENSIVE CARE; INTESTINE ISCHEMIA; LOADING DRUG DOSE; MALE; MESENTERIC VEIN THROMBOSIS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECURRENT INFECTION; SEPSIS; SMALL INTESTINE RESECTION;

AGED; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDEMIA; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; MALE; MUTATION;

EID: 84861144330     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06100-11     Document Type: Article

References (25)

1. Aguado JM, et al. 2011. Recomendaciones sobre el tratamiento de la candidiasis invasiva y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm. Infecc. Microbiol. Clin. 29:345-361.
2. Arendrup MC, et al. 2011. EUCAST technical note on anidulafungin. Clin. Microbiol. Infect. 17:E18-E20.
3. Arendrup MC, et al. 2010. Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and IsoSensitest media. Antimicrob. Agents Chemother. 54:426-439.
4. Chapeland-Leclerc F, et al. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob. Agents Chemother. 54:1360-1362.
5. Clamp M, Cuff J, Searle SM, Barton GJ. 2004. The Jalview Java alignment editor. Bioinformatics 20:426-427. (Pubitemid 38262778)
6. Cleary JD, García-Effron G, Chapman SW, Perlin DS. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265. (Pubitemid 351758575)
7. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. CLSI, Wayne, PA.
8. Costa-de-Oliveira S, et al. 2011. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob. Agents Chemother. 55:1312-1314.
9. Foulet F, et al. 2005., Microsatellite marker analysis as a typing system for Candida glabrata. J. Clin. Microbiol. 43:4574-4579. (Pubitemid 41298245)
10. García-Effron G, et al. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54:2225-2227.
11. García-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699.
12. Hunter PR, Gaston MA. 1988. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. J. Clin. Microbiol. 26:2465-2466.
13. Ortega M, et al. 2011. Candida species bloodstream infection: epidemiology and outcome in a single institution from 1991 to 2008. J. Hosp. Infect. 77:157-161.
14. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
15. Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130. (Pubitemid 47031054)
16. Pfaller M, et al. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 49:624-629.
17. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretative criteria. Drug Resist. Updat. 14:164-176.
18. Pfaller MA, et al. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. J. Clin. Microbiol. 48:1592-1599.
19. Rodríguez D, et al. 2010. Predictors of candidaemia caused by nonalbicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin. Microbiol. Infect. 16:1676-1682.
20. Rodríguez-Hernández MJ, et al. 2011. Candidemias: análisis multicéntrico en 16 hospitales andaluces. Enferm. Infecc. Microbiol. Clin. 29:328-333.
21. Rodriguez-Tudela JL, et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405. (Pubitemid 351356536)
22. Sun H-Y, Singh N. 2010. Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review. Int. J. Antimicrob. Agents. 353:211-218.
23. Tang CM, Cohen J, Holden DW. 1992. An Aspergillus fumigatus alkaline protease mutant constructed by gene disruption is deficient in extracellular elastase activity. Mol. Microbiol. 6:1663-1671.
24. Thompson GR, et al. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
25. Zimbeck AJ, et al. 2010. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob. Agents Chemother. 54:5042-5047.